Scarica l'app Stockscreener
7.74
4.33%
-0.35
Dopo l'orario di chiusura:
7.77
0.03
+0.39%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$8.09
Aprire:
$8.09
Volume 24 ore:
38,524
Relative Volume:
0.55
Capitalizzazione di mercato:
$14.58M
Reddito:
-
Utile/perdita netta:
$-26.56M
Rapporto P/E:
-0.175
EPS:
-44.2199
Flusso di cassa netto:
$-28.59M
1 W Prestazione:
-13.52%
1M Prestazione:
-24.78%
6M Prestazione:
+148.87%
1 anno Prestazione:
-3.55%
Intervallo 1D:
$7.65
$8.27
Intervallo di 1 settimana:
$6.5535
$9.73
Portata 52W:
$0.61
$14.68
Briacell Therapeutics Corp Stock (BCTX) Company Profile
Nome
Briacell Therapeutics Corp
Settore
Industria
Telefono
(604) 921-1810
Indirizzo
3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR, WEST VANCOUVER
Confronta BCTX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BCTX
Briacell Therapeutics Corp
|
7.74 | 15.24M | 0 | -26.56M | -28.59M | -44.22 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.90 | 117.47B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
784.97 | 82.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.59 | 52.94B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
844.92 | 52.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.88 | 37.84B | 447.02M | -1.18B | -906.14M | -6.1812 |
Briacell Therapeutics Corp Stock (BCTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2022-02-14 | Iniziato | H.C. Wainwright | Buy |
Briacell Therapeutics Corp Borsa (BCTX) Ultime notizie
Why BriaCell Therapeutics Corp. Equity Warrant stock is favored by pension fundsProtective Put Strategies & Big Profit Low Trading - bollywoodhelpline.com
(BCT) Trading Signals (BCT:CA) - Stock Traders Daily
Form FWP BriaCell Therapeutics Filed by: BriaCell Therapeutics Corp. - StreetInsider
Profit Review: Why BriaCell Therapeutics Corp. stock remains undervaluedJuly 2025 Sector Moves & Expert-Curated Trade Recommendations - Улправда
Why hedge funds are buying BriaCell Therapeutics Corp. Equity Warrant stockMarket Activity Report & Risk Controlled Daily Plans - Улправда
Market Recap: How BriaCell Therapeutics Corp. Equity Warrant stock reacts to Fed rate cutsWeekly Stock Summary & Safe Entry Point Alerts - Улправда
Is BriaCell Therapeutics Corp. Equity Warrant stock oversold or undervaluedChart Signals & Fast Moving Trade Plans - Улправда
How BriaCell Therapeutics Corp. Equity Warrant stock reacts to Fed rate cutsCPI Data & Verified Momentum Stock Alerts - Улправда
Is BriaCell Therapeutics Corp. stock a buy for dividend growth2025 Sector Review & Reliable Breakout Forecasts - Улправда
Is BriaCell Therapeutics Corp. Equity Warrant stock recession proof2025 Year in Review & Technical Pattern Based Signals - Улправда
Will BriaCell Therapeutics Corp. stock gain from strong economyBuy Signal & Daily Stock Trend Reports - DonanımHaber
Is BriaCell Therapeutics Corp. stock a safe haven assetMarket Sentiment Summary & Technical Pattern Based Signals - DonanımHaber
Why BriaCell Therapeutics Corp. stock could benefit from AI revolutionJuly 2025 Opening Moves & Smart Investment Allocation Tips - DonanımHaber
BriaCell’s phase 3 breast cancer trial named a 2026 ‘clinical trial to watch’ by Nature Medicine - MSN
Why BriaCell Therapeutics Corp. stock remains undervalued2025 Growth vs Value & High Win Rate Trade Tips - Улправда
BriaCell’s Phase 3 Breast Cancer Trial Named a 2026 ‘Clinical Trial to Watch’ by Nature Medicine - TipRanks
"Eleven clinical trials that will shape medicine in 2026"BriaCell Phase 3 Trial Featured in Nature Medicine - Investing News Network
Briacell phase 3 trial featured in Nature Medicine - marketscreener.com
'Eleven clinical trials that will shape medicine in 2026”BriaCell Phase 3 Trial Featured in Nature Medicine - The Manila Times
Briacell Phase 3 Trial Featured In Nature Medicine - TradingView — Track All Markets
“Eleven clinical trials that will shape medicine in 2026” – BriaCell Phase 3 Trial Featured in Nature Medicine - GlobeNewswire
Why one metastatic breast cancer trial is a key one to watch in 2026 - Stock Titan
BriaCell Therapeutics : Fact Sheet (20251216 Fact Sheet) - marketscreener.com
BriaCell Therapeutics : Investor Presentation (20251216 Website Presentation) - marketscreener.com
How to Take Advantage of moves in (BCT) (BCT:CA) - news.stocktradersdaily.com
Why Institutions Believe Bondada Engineering Limited Is Undervalued TodayMarket Liquidity Analysis & Build Wealth With Zero-Cost Tools - earlytimes.in
Rally Mode: What insider trading reveals about BriaCell Therapeutics Corp stockIPO Watch & Comprehensive Market Scan Insights - moha.gov.vn
(BCT) Trading Performance and Risk Management (BCT:CA) - news.stocktradersdaily.com
Top 3 Earnings Acceleration Buys for November - MSN
BriaCellModel Bria-IMT and Bria-OTSDestroy Cancer Cells - Environmental XPRT
BriaCell Therapeutics Corp. Reports Earnings Results for the First Quarter Ended October 31, 2025 - marketscreener.com
BriaCell (NASDAQ: BCTX) boosts R&D as going concern risk emerges - Stock Titan
BriaCell’s Bria-IMT shows promising results in metastatic breast cancer trials - MSN
BriaCell Therapeutics Corp Warrant 2021-26.02.26 on BriaCell Therapeutics - TradingView — Track All Markets
Net income of BriaCell Therapeutics Corp Warrant 2021-26.02.26 on BriaCell Therapeutics – NASDAQ:BCTXW - TradingView — Track All Markets
BriaCell reports positive data for breast cancer immunotherapy By Investing.com - Investing.com Nigeria
BriaCell (BCTX) Highlights Promising Data at 2025 SABCS Symposiu - GuruFocus
BriaCell’s Bria-IMT Shows Promising Results in Metastatic Breast Cancer Trials - TipRanks
BriaCell Presents Outstanding Phase 2 Survival & Promising Phase 3 Clinical Data at SABCS® 2025 - Investing News Network
BriaCell reports positive data for breast cancer immunotherapy - Investing.com
BriaCell (BCTX) Progresses with Phase 3 Study in Metastatic Brea - GuruFocus
BriaCell’s Phase 3 Study on Track for 2026 Data Readout - TipRanks
BriaCell's Phase 3 Patient Enrollment on Track for 1H2026 Topline Data Readout - Investing News Network
BriaCell’s Phase 3 Patient Enrollment on Track for 1H2026 Topline Data Readout - The Manila Times
Briacell's phase 3 patient enrollment on track for 1H2026 topline data readout - marketscreener.com
BriaCell's Phase 3 Patient Enrollment On Track For 1H2026 Topline Data Readout - TradingView — Track All Markets
Movement Recap: Will BriaCell Therapeutics Corp Equity Warrant stock outperform Dow Jones indexJuly 2025 Sector Moves & Expert-Curated Trade Recommendations - moha.gov.vn
BriaCell Therapeutics (BCTXZ) Stock Analysis Report | Financials & Insights - Benzinga
BriaCell Unveils Promising Clinical Data at 2025 SABCS - MSN
BriaCell Therapeutics : Investor Presentation (1Dec2025 Investor Presentation) - marketscreener.com
Will BriaCell Therapeutics Corp. Equity Warrant stock outperform Dow Jones indexQuarterly Profit Report & Long-Term Investment Growth Plans - Newser
Briacell Therapeutics Corp Azioni (BCTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.08%
0.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):